Skip Navigation

S2302, PRAGMATICA ? LUNG: ?A Prospective Randomized Study of Ramucirumab LY3009806; NSC 749128 plus Pembrolizumab MK-3475; NSC 776864 versus Standard of Care for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer.?

Brief Summary

Lung Cancers

Study Type:

III Identifier:

Study #:

Start Date:
May 17, 2023

Full Details and Eligibility at

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below. ID: NCT05633602

View Complete Trial Details & Eligibility at